B of A Securities Maintains Underperform on Sage Therapeutics, Lowers Price Target to $6
B of A Securities Maintains Underperform on Sage Therapeutics, Lowers Price Target to $6
美銀證券維持對sage therapeutics的賣出評級,並將價格目標下調至6美元
B of A Securities analyst Tazeen Ahmad maintains Sage Therapeutics (NASDAQ:SAGE) with a Underperform and lowers the price target from $11 to $6.
美銀證券分析師Tazeen Ahmad維持對Sage Therapeutics(納斯達克股票代碼:SAGE)的賣出評級,並將價格目標從11美元降至6美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。